
Pediatrix Medical Group, Inc. (NYSE:MD – Free Report) – Research analysts at Zacks Research boosted their FY2026 earnings per share estimates for Pediatrix Medical Group in a research report issued on Tuesday, August 18th. Zacks Research analyst Team now anticipates that the company will earn $2.11 per share for the year, up from their prior estimate of $2.02. The consensus estimate for Pediatrix Medical Group’s current full-year earnings is $2.15 per share. Zacks Research also issued estimates for Pediatrix Medical Group’s Q2 2027 earnings at $0.53 EPS.
Pediatrix Medical Group (NYSE:MD – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The business had revenue of $487.78 million during the quarter, compared to analysts’ expectations of $478.49 million. During the same quarter last year, the business posted $0.53 EPS. The business’s quarterly revenue was up 4.1% compared to the same quarter last year.
View Our Latest Stock Report on Pediatrix Medical Group
Pediatrix Medical Group Stock Performance
Shares of MD opened at $26.16 on Friday. The stock has a 50 day moving average price of $25.72 and a 200 day moving average price of $22.95. Pediatrix Medical Group has a 52-week low of $15.69 and a 52-week high of $27.94. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of 12.52 and a beta of 0.66.
Hedge Funds Weigh In On Pediatrix Medical Group
A number of hedge funds have recently made changes to their positions in MD. Keybank National Association OH lifted its holdings in Pediatrix Medical Group by 2.0% in the 1st quarter. Keybank National Association OH now owns 22,941 shares of the company’s stock worth $491,000 after buying an additional 458 shares in the last quarter. Gotham Asset Management LLC grew its stake in shares of Pediatrix Medical Group by 0.6% during the third quarter. Gotham Asset Management LLC now owns 116,093 shares of the company’s stock valued at $1,945,000 after acquiring an additional 724 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Pediatrix Medical Group by 4.6% during the fourth quarter. ProShare Advisors LLC now owns 16,816 shares of the company’s stock worth $360,000 after acquiring an additional 734 shares during the last quarter. Verition Fund Management LLC lifted its stake in shares of Pediatrix Medical Group by 4.4% in the third quarter. Verition Fund Management LLC now owns 25,408 shares of the company’s stock worth $426,000 after acquiring an additional 1,066 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Pediatrix Medical Group by 77.7% in the first quarter. EverSource Wealth Advisors LLC now owns 2,515 shares of the company’s stock worth $54,000 after acquiring an additional 1,100 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.
Pediatrix Medical Group News Summary
Here are the key news stories impacting Pediatrix Medical Group this week:
- Positive Sentiment: Zacks raised several earnings forecasts: Estimates increased for FY2026 EPS to $2.11 from $2.02, FY2027 EPS to $2.10 from $1.94, and FY2028 EPS to $2.04 from $1.88. Quarterly estimates were also lifted for Q1 2027, Q2 2027, Q3 2027 and Q4 2027. The revisions suggest improving confidence in Pediatrix’s future profitability.
- Positive Sentiment: Momentum sentiment remains supportive. A Zacks article characterized Here’s Why Pediatrix Medical Group Is a Strong Momentum Stock Pediatrix Medical Group as a strong momentum stock, reinforcing the recent positive trend in investor sentiment.
- Neutral Sentiment: Forecasts remain close to consensus. Zacks’ FY2026 estimate of $2.11 per share is slightly below the current consensus of $2.15, indicating that the upgrades are constructive but do not represent a major change in the broader earnings outlook.
- Negative Sentiment: One longer-term estimate was reduced. Zacks lowered its Q1 2028 EPS forecast to $0.34 from $0.36, partially offsetting the other upward revisions and highlighting some uncertainty around longer-term quarterly performance.
About Pediatrix Medical Group
Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.
Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.
Recommended Stories
- Five stocks we like better than Pediatrix Medical Group
- Coherent Stock Is Cooling Off Just as Its AI Thermal Opportunity Heats Up
- Moderna’s 177% Surge Has Investors Asking What Comes Next
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
